⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
globenewswire.com
RVMD
REVA Medical Announces Positive MOTIV BTK Trial Results Showing Superiority in Patients with Critical Limb-Threatening Ischemia USA - English USA - English
prnewswire.com
RVMD
Capture More Revenue Without Adding Patients Using RevolutionEHR’s Dr. Contact Lens Integration
businesswire.com
RVMD
PRCT
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
globenewswire.com
RVMD
Form 8-K
sec.gov
RVMD
RVMDW
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com
RVMD
Form 8-K
sec.gov
RVMD
RVMDW
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
globenewswire.com
RVMD
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
globenewswire.com
RVMD
Form 8-K
sec.gov
RPRX
RVMD